Long-term Follow-up of RESTORE Study
Launched by BLUE NOTE THERAPEUTICS · Dec 9, 2022
Trial Information
Current as of November 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolled in and not withdrawn from the original RESTORE study
About Blue Note Therapeutics
Blue Note Therapeutics is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for mental health disorders. With a focus on leveraging cutting-edge technology and evidence-based approaches, Blue Note Therapeutics aims to transform the treatment landscape for patients suffering from conditions such as anxiety and depression. The company's commitment to scientific rigor and patient-centered care drives its clinical development programs, fostering collaborations with leading researchers and healthcare professionals to ensure the delivery of safe and effective therapeutic solutions. Through its initiatives, Blue Note Therapeutics aspires to improve the quality of life for individuals facing mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Dianne M Shumay, PhD
Principal Investigator
Blue Note Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials